

Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes

*Original*

Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes / Zaccaria, Gian Maria; Ferrero, Simone; Rosati, Samanta; Ghislieri, Marco; Genuardi, Elisa; Evangelista, Andrea; Sandrone, Rebecca; Castagneri, Cristina; Barbero, Daniela; Lo Schirico, Mariella; Arcaini, Luca; Molinari, Anna Lia; Ballerini, Filippo; Ferreri, Andres; Omedè, Paola; Zamò, Alberto; Balestra, Gabriella; Boccadoro, Mario; Cortelazzo, Sergio; Ladetto, Marco. - In: JCO CLINICAL CANCER INFORMATICS. - ISSN 2473-4276. - ELETTRONICO. - 3:3(2019), pp. 1-15-15. [10.1200/CCI.19.00049]

*Availability:*

This version is available at: 11583/2764439 since: 2019-12-18T14:01:49Z

*Publisher:*

American Society of Clinical Oncology (ASCO)

*Published*

DOI:10.1200/CCI.19.00049

*Terms of use:*

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

*Publisher copyright*

(Article begins on next page)

# Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes

Gian Maria Zaccaria, PhD<sup>1</sup>; Simone Ferrero, MD<sup>1</sup>; Samanta Rosati, PhD<sup>2</sup>; Marco Ghislieri, MSc<sup>2</sup>; Elisa Genuardi, PhD<sup>1</sup>; Andrea Evangelista, PhD<sup>3</sup>; Rebecca Sandrone, MSc<sup>2</sup>; Cristina Castagneri, MSc<sup>2</sup>; Daniela Barbero, PhD<sup>1</sup>; Mariella Lo Schirico, MD<sup>4</sup>; Luca Arcaini, MD<sup>5</sup>; Anna Lia Molinari, MD<sup>6</sup>; Filippo Ballerini, MD<sup>7</sup>; Andres Ferreri, MD<sup>8</sup>; Paola Omedè, PhD<sup>1</sup>; Alberto Zamò, PhD<sup>1</sup>; Gabriella Balestra, PhD<sup>2</sup>; Mario Boccadoro, MD<sup>1</sup>; Sergio Cortelazzo, MD<sup>9</sup>; and Marco Ladetto, MD<sup>10</sup>

## abstract

**PURPOSE** Data collection in clinical trials is becoming complex, with a huge number of variables that need to be recorded, verified, and analyzed to effectively measure clinical outcomes. In this study, we used data warehouse (DW) concepts to achieve this goal. A DW was developed to accommodate data from a large clinical trial, including all the characteristics collected. We present the results related to baseline variables with the following objectives: developing a data quality (DQ) control strategy and improving outcome analysis according to the clinical trial primary end points.

**METHODS** Data were retrieved from the electronic case reporting forms (eCRFs) of the phase III, multicenter MCL0208 trial (ClinicalTrials.gov identifier: [NCT02354313](https://clinicaltrials.gov/ct2/show/study/NCT02354313)) of the Fondazione Italiana Linfomi for younger patients with untreated mantle cell lymphoma (MCL). The DW was created with a relational database management system. Recommended DQ dimensions were observed to monitor the activity of each site to handle DQ management during patient follow-up. The DQ management was applied to clinically relevant parameters that predicted progression-free survival to assess its impact.

**RESULTS** The DW encompassed 16 tables, which included 226 variables for 300 patients and 199,500 items of data. The tool allowed cross-comparison analysis and detected some incongruities in eCRFs, prompting queries to clinical centers. This had an impact on clinical end points, as the DQ control strategy was able to improve the prognostic stratification according to single parameters, such as tumor infiltration by flow cytometry, and even using established prognosticators, such as the MCL International Prognostic Index.

**CONCLUSION** The DW is a powerful tool to organize results from large phase III clinical trials and to effectively improve DQ through the application of effective engineered tools.

JCO Clin Cancer Inform. © 2019 by American Society of Clinical Oncology

## INTRODUCTION

The complexity of translational clinical trials has led to increased amounts of collected data, which need to be stored and properly managed. In this context, electronic tools are increasingly used for clinical data collection.<sup>1</sup> However, the mere collection and storage of data are insufficient to fulfill clinicians' current need to access all information contained in clinical trials, which often include unique sources of information for a wide array of clinical and biologic correlates. A data warehouse (DW) is a "subject-oriented, integrated, time-variant, and nonvolatile collection of data in support of management's decision making process."<sup>2(p126)</sup> Although the use of DWs in the business domain was established several years ago, its application in health care is still in its infancy.<sup>3-5</sup> In contrast to a database, a DW is designed to support users in the analysis of

longitudinal long-term data,<sup>6</sup> allowing high-level integration from different data sources.<sup>7-9</sup> These characteristics might make DWs a suitable tool for the data management of clinical trials.<sup>10</sup> A DW is a relational model in which data are stored in tables that are connected by means of relations. In each table, rows represent the records or occurrences and columns refer to attributes or variables.<sup>2</sup>

Given that the main aim of a DW is to support the decision-making process,<sup>11</sup> the most critical aspect is not simply data storing but rather to ensure the data quality (DQ)—in terms of conformance, completeness, correctness, plausibility, and consistency—is adequate to produce meaningful information.<sup>12-15</sup> This is true for both clinical and molecular data. Moreover, the periodic management of the DQ during clinical trials might reduce the effects of different

## ASSOCIATED CONTENT

### Data Supplement

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on August 30, 2019 and published at [ascopubs.org/journal/cci](https://ascopubs.org/journal/cci) on October 21, 2019; DOI <https://doi.org/10.1200/CCI.19.00049>

## CONTEXT

### Key Objective

To develop a data warehouse model to accommodate both clinical and biologic data from a phase III, open-label, multicenter clinical trial on mantle cell lymphoma (MCL) aimed to improve data quality according to the clinical end points of the study.

### Knowledge Generated

The implementation of data warehousing concepts allows us to systematically define a data quality (DQ) control strategy to both facilitate clinical sponsors in handling the clinical trial management and to improve the centers' accuracy in compiling electronic case report forms. The DQ effectiveness affects clinical end points of the study as the prognostic stratification according to single parameters, such as tumor infiltration by flow cytometry, and even using established prognosticators, such as the MCL International Prognostic Index.

### Relevance

Our findings demonstrate that data warehousing concepts provide a powerful tool to organize results from large phase III clinical trials and to effectively improve DQ through the application of engineered tools.

data-handling approaches on the obtained information.<sup>16-20</sup> To obtain high-quality data, several recommended DQ dimensions might be studied to highlight missing, not plausible, incorrect, or nonconcordant values in time and across recruiting centers. Nevertheless, it is well known that all these aspects might compromise the quality of information retrieved from data as reported recently,<sup>20</sup> because data completeness is often the most commonly assessed dimension of DQ.

In clinical studies, the successful assessment of new knowledge about a certain disease or treatment in different clinical and biologic settings is also strongly linked to the periodic measurement of performance.<sup>21</sup> Therefore, the objective monitoring of study productivity, DQ, and the knowledge returned from data should be considered. Hence, the aim of the study was to introduce a DW for the data collection of a prospective, multicenter Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial. In addition, we aimed to describe its potential role in monitoring accuracy when compiling electronic case report forms (eCRFs) and the centers' compliance with the management of patients' specimens. Our results highlight how a DW approach improved the assessment of clinical outcomes in patients with mantle cell lymphoma (MCL) and provided an accurate definition of the prognostic index, such as the MCL International Prognostic Index (MIPI),<sup>22</sup> and biologic parameters, such as tissue tumor infiltration detected by flow cytometry.

## METHODS

### Patients


The data used in this study were collected from a phase III, multicenter, open-label, randomized, controlled clinical trial primarily aiming to determine the efficacy and safety of lenalidomide as maintenance therapy versus observation in younger ( $\leq 65$  years) patients affected by advanced-stage MCL. Patients achieving at least a partial response after an upfront treatment with rituximab were supplemented with

high-dose immunochemotherapy and autologous stem-cell transplantation (FIL-MCL0208 trial; ClinicalTrials.gov identifier: [NCT02354313](https://clinicaltrials.gov/ct2/show/study?term=NCT02354313)); the details of the treatment schedule have already been presented elsewhere, together with the clinical results.<sup>23</sup> The manuscript presenting the clinical outcome of the trial is in preparation. Overall, 300 patients were enrolled from May 2010 to August 2015 at 48 Italian and one Portuguese center.

Data presented in this manuscript are derived from the final analysis, planned after the observation of 60 post-randomization events of progression-free survival (PFS), which occurred on March 3, 2018. The study was conducted in accordance with the Declaration of Helsinki, and all patients provided written informed consent for the collection and research use of clinical and biologic data. Because of its translational characterization, FIL-MCL0208 was an ideal candidate trial to test our methods. In particular, it involved several ancillary studies, for a global number of data items of 199,500. To conduct ancillary studies, the management of patient samples was coordinated by the central secretariat of the FIL.

### Database Description and DW Design

In the context of the clinical trial, several variables were acquired. Data were retrieved from both the eCRFs compiled by the clinical centers and the data sets provided by the centralized molecular biology laboratory. Patients' characteristics were assessed at diagnosis (baseline) and at different predefined time points during the study. Starting from the analysis of the variables recorded in the eCRFs, we built up a DW to collect all clinical and biologic data in an organized structure. The DW was organized around a table collecting the demographic information of all enrolled patients, according to Inmon.<sup>2</sup> All other tables recording the clinical data were linked to this one by means of proper relationships. In every table, a key attribute was defined as a unique value for each record. Hence, the linkage with the central table was achieved by connecting the respective



**FIG 1.** Structure of the data warehouse (DW) for the collection of data recorded in the electronic case reporting forms (eCRFs) and in the data sources from laboratories during the clinical trial. The DW had a snowflake architecture. The subject table represented the center of the DW design and was directly connected to other categories: Protocol Data, Laboratory Data, Pathologic Data, (continued on following page)

key attribute via the unique attribute codeSubjects, which is the patient's identification (ID) defined by the trial sponsor. Overall, each table was designed to collect variables related to the same category. For example, the classic laboratory variables were organized in the Laboratory\_Data table. The common data model (CDM) was implemented and populated by Oracle MySQL, version 5.5.9, an open-source relational database management system based on the Structured Query Language for programming.

### DQ Management Procedure

For the DQ analysis of baseline attributes, we considered the extensive effort involved in data collection, and we speculated that several incongruencies could compromise the overall DQ. First, we identified the relevant variables from the pool saved in the DW according to the clinical trial end points.<sup>24,25</sup> Hence, recommended DQ dimensions were investigated across data<sup>14</sup>:

Atemporal completeness (C): related to the number of missing values (MVs).

Atemporal plausibility (P): defined by “whether or not the values or data points are believable when compared to the expected representation of an accepted value range distribution”<sup>14(p1081)</sup> (eg, WBC filled in eCRFs as either  $10^9/L$  or  $10^6/L$ , Ki67 proliferation index<sup>26</sup> and lactate dehydrogenase [LDH] levels set as 0).

Atemporal concordance (CON): measures “the agreement between elements”<sup>20(p147)</sup> (eg, bone marrow infiltration [BMinf] detected by immunochemistry with Ann Arbor [AA] staging<sup>27</sup> < 4).

The DQ dimensions were assessed dividing the count of expected values of fields considered relevant<sup>24</sup> according to each group set up in the DW minus the count of detected incongruities, by the number of expected values. Moreover, each dimension was studied across 49 active centers, which were classified in large ( $\geq 10$  patients enrolled), medium (between 5 and 9 patients enrolled), and small ( $< 5$  patients enrolled). According to temporality dimension, since the study start (No\_DQ time point), this procedure of DQ was performed four times (DQ post-milestones [PM], every 6 months: PM-1, PM-2, PM-3, and PM-4), and the DW was regularly updated accordingly to the changes in the data sources. A Student *t* test (paired, two-tail, significance level:  $\alpha = .05$ ) was applied to each DQ dimension calculated between No\_DQ and PM-4 time points to assess whether the increase of the overall DQ was significant across centers.

Second, we verified the validity of conformance, correctness, granularity, and structuredness dimensions,<sup>20</sup> respectively. All pitfalls were systematically integrated in the extraction, transformation, and loading (ETL) process by means of an ad hoc automatic routine developed in the Matlab environment (R2018a). A report containing a detailed description of the identified inconsistencies was generated for each center as queries, requesting an amendment of the eCRF data after every milestone.

### Survival Analysis

Repeated PFS analyses were performed after each DQ milestone to assess the impact of DQ management. We chose one universally recognized multiparametric parameter (ie, the MIPI), together with baseline flow cytometry, a parameter that seemed to be associated with more missing values, as it was not frequently reported in MCL trials. The PFS was calculated from the date of enrollment in the clinical study to the date of disease progression (event), death from any cause (event), or last follow-up (censoring).<sup>28</sup> The PFS was estimated using the Kaplan-Meier model and compared between groups using the log-rank test ( $\alpha = .05$ ). The PFS curves were plotted both before and after applying the DQ management procedure via the R package 3.4.1, as of 2017. The results of the log-rank test are reported in terms of the *P* values obtained when comparing the curves of two adjacent classes.

## RESULTS

### DW Structure

Figure 1 shows the structure of the DW for the collection of data recorded in the eCRFs during the clinical trial. The DW consisted of 16 tables containing 226 features. In the figure, tables presenting data related to the same category were grouped together. The Demographic & Morphometric data group (table subject) represented the center of the DW design and was directly connected to additional categories. Hence, the DW structure assumed a “snowflake” architecture.<sup>7,29</sup>

For those categories where data were collected both at the baseline and at each restaging during the clinical follow-up, two different approaches were used for the DW design. First, if the same variables were acquired exactly the same way at each time point, only one table was used for their storage, containing an attribute related to the time point (N\_timepoint). This was the case for both laboratory\_data and diag\_procedures tables. Second, two tables were implemented in the CDM for those patients for whom different information needed to be registered at baseline

**FIG 1.** (Continued). Clinical Data, Imaging Data, and Minimal Residual Disease (MRD) Data tables. Three auxiliary tables were used in the Imaging Data category to encode the supra-diaphragmatic, sub-diaphragmatic, and extranodal involvements. The MRD Data category contained the information of both IgH and BCL1 biomarkers detected by both nested (qualitative) and real-time quantitative polymerase chain reaction in bone marrow (BM) and peripheral blood (PB) at baseline (mrd\_baseline table); the MRD analysis was performed to monitor minimal residual disease on IgH and BCL1 markers from both BM and PB at each restaging (mrd\_restaging table) and after the leukapheresis procedure (mrd\_lk table). DQ, data quality.

**TABLE 1.** Description of the Principal Variables Encoded in the DW

Variable	Class of Data	Validity Range	Unit of Measure	Description	Source
ID	—	—	—	Primary key of the table; it is the internal ID of the table	eCRF
codeSubject	Protocol	0-9,999	—	Unique ID of the accrued subjects. This ID code is defined by the clinical trial sponsor	
Center_ID	Protocol	0-99	—	Unique ID of enrolling centers	
Age	Demographic	0-99	years	Age at diagnosis	
Sex	Demographic	0-1	—	0: male; 1: female	
W	Morphometric	0-999	kg	Weight	
H	Morphometric	0-999	cm	Height	
BMI	Morphometric	0-9	kg/m <sup>2</sup>	BMI = (W/H) <sup>2</sup>	
BSA	Morphometric	0-9	m <sup>2</sup>	BSA = [(H × W)/3,600] <sup>0.5</sup>	
idCenter	—	—	—	Primary key of the table; it is the internal ID of the table. It is related to Center_ID attribute from subject table	eCRF
Name	Protocol	—	—	Name of the center	
idProtocol	—	—	—	Primary key of the table; it is the internal ID of the table	eCRF
codeSubject	Protocol	0-9,999	—	It is the unique ID of the accrued subjects. This ID code is defined by the clinical trial sponsor	
PFS	Protocol	0-1	—	0: no progression or death or censored event recorded; 1: progression or death or censored event recorded	
Progression	Protocol	0-1	—	0: no progression or censored event recorded; 1: progression or censored event recorded	
OS	Protocol	0-1	—	0: no death or censored event recorded; 1: death or censored event recorded	
Date_Consent	Protocol	—	—	Date time of the signature by the patient of the informed consent	
PFS_Date	Protocol	—	—	Progression or death or censored event date	
OS_Date	Protocol	—	—	Death or censored event date	
Arm	Protocol	0-1	—	Arm of treatment. 0: patient randomly assigned in arm A; 1: patient randomly assigned in arm B	
RND	Protocol	0-1	—	Random assignment. 0: patient not randomly assigned; 1: patient randomly assigned	
RND_date	Protocol	—	—	Date of random assignment	
Study_Interrupted	Protocol	0-1	—	0: treatment not interrupted; 1: treatment interrupted	
Study_Interruption_ID	Protocol	0-99	—	Unique ID of the type of the interruption of the study. This code is defined by the eCRFs designer	
Study_Interr_Date	Protocol	—	—	Date of the interruption of the study	
idStudy_Interruption	—	—	—	Primary key of the table; it is the internal ID of the table	eCRF
Name	Protocol	—	—	1: adverse event; 2: withdrawal of consent, not due to adverse event; 3: poor compliance; 4: serious breach of the protocol; 5: progression; 6: decision of the principal investigator of the study; 7: dispersed during the study; 8: other; 9: death	
ID	—	—	—	Primary key of the table; it is the internal ID of the table	eCRF
codeSubject	Protocol	0-9,999	—	Unique ID of the accrued subjects. This ID code is defined by the clinical trial sponsor	
LDH	Laboratory	0-9,999	mg/dL	Lactate dehydrogenase	
LDHMax	Laboratory	0-9,999	mg/dL	Maximum level of LDH for laboratory	
LDHHigh	Laboratory	0-1	—	0: LDH < LDHMax; 1: LDH ≥ LDHMax	

(Continued on following page)

**TABLE 1.** Description of the Principal Variables Encoded in the DW (Continued)

Variable	Class of Data	Validity Range	Unit of Measure	Description	Source
WBC	Laboratory	0-99	10 <sup>9</sup> /L	WBC count	
ANC	Laboratory	0-99	10 <sup>9</sup> /L	Absolute neutrophil count	
L	Laboratory	0-99	10 <sup>9</sup> /L	Lymphocytes level	
Hb	Laboratory	0-99	g/dL	Hemoglobin level	
PLTs	Laboratory	0-999	10 <sup>9</sup> /L	Platelets level	
Protein	Laboratory	0-9	g/dL	Total proteins in blood	
Alb	Laboratory	0-9	g/dL	Albumin	
B2	Laboratory	0-9	mg/dL	β <sub>2</sub> microglobulin level	
B2Max	Laboratory	0-9	mg/dL	Maximum level of B2 for laboratory	
B2onB2Max	Laboratory	0-9	—	Normalized value of B2 on max	
IgG	Laboratory	0-9	g/dL	Immunoglobulin G level	
N_timepoint	Temporal	0-9	—	0: baseline; 1: restaging1; 2: restaging2; 3: restaging3; 4: FU1; 5: FU2; 6: FU3; 7: FU4; 8: FU5	
ID	—	—	—	Primary key of the table: it is the internal ID of the table	eCRF
codesSubject	Protocol	—	—	Unique ID of the accrued subjects. This ID code is defined by the clinical trial sponsor	
flowBM	Pathologic	0-999	%	Tumor infiltration value from bone marrow detected by flow cytometry	
flowPB	Pathologic	0-999	%	Tumor infiltration value from peripheral blood detected by flow cytometry	
Hist	Pathologic	0-1	—	Local evaluation of the histology. 0: normal histology; 1: blastoid histology	
Ki67	Pathologic	0-999	%	Proliferation index calculated on bone marrow; calculated by local laboratory	
BMIInf	Pathologic	0-1	%	0: bone marrow not infiltrated by immunochemistry; 1: bone marrow infiltrated by immunochemistry	
IgHOmo	Pathologic	0-999	%	Omology to IgH germline configuration	
SOX11	Pathologic	0-1	—	Protein responsible for neural transcription, found to be overexpressed in leukemic MCL cells. Calculated by local laboratory	
ID	—	—	—	0: not expressed; 1: expressed	
codeSubject	Clinical	0-9,999	—	Primary key of the table: it is the internal ID of the table	eCRF
AASstage	Clinical	0-9	—	Unique ID of the accrued subjects. This ID code is defined by the clinical trial sponsor	
ECOGps	Clinical	0-9	—	AA stage shows whether the MCL is in one area of body (localized) or has spread to other areas. AASstage may assume a discrete value from 1 to 4	
MIPICRF	Clinical	0-99	—	Eastern Cooperative Oncology Group performance status <sup>38</sup>	
RCMIPICRF	Clinical	0-9	—	ECOG may assume a discrete value from 0 to 4	
MIPISi	Clinical	0-99	—	MIPi standard from eCRFs according to Hoster et al <sup>22</sup>	
MIPISim	Clinical	0-99	—	Glass risk of relapse based on MIPICRF according to Hoster et al <sup>22</sup>	
				Automatic MIPi standard assessment according to Hoster et al <sup>22</sup>	
				Automatic MIPi simplified assessment according to Hoster et al <sup>22</sup>	

(Continued on following page)



**TABLE 1.** Description of the Principal Variables Encoded in the DW (Continued)

Variable	Class of Data	Validity Range	Unit of Measure	Description	Source
MIPIBIol	Clinical	0-99	—	Automatic MIPI biologic assessment according to Hoster et al <sup>22</sup>	
RCMIPISt	Clinical	0-9	—	Class risk of relapse based on MIPISt according to Hoster et al <sup>22</sup>	
RCMIPISim	Clinical	0-9	—	Class risk of relapse based on MIPISim according to Hoster et al <sup>22</sup>	
RCMIPIBIol	Clinical	0-9	—	Class risk of relapse based on MIPIBIol according to Hoster et al <sup>22</sup>	
MIPIcSt	Clinical	0-9	—	Automatic MIPI-c assessment from MIPISt according to Hoster et al <sup>22</sup>	
MIPIcSim	Clinical	0-9	—	Automatic MIPI-c assessment from MIPISim according to Hoster et al <sup>22</sup>	
Bulky	Clinical	0-1	—	Tumor bulk. 0: < 5 cm; 1: ≥ 5 cm	
Sym	Clinical	0-1	—	MCL symptoms class according to Mallick, Lai, and Daugherty <sup>39</sup> . 0: A symptoms; 1: B symptoms	
idDP	—	—	—	Primary key of the table: it is the internal ID of the table	eCRF
codeSubject	Protocol	0-9,999	—	Unique ID of the accrued subjects. This ID code is defined by the clinical trial sponsor	
N_timepoint	Temporal	0-9	—	0: baseline, 1: restaging1; 2: restaging2; 3: restaging3; 4: FU1; 5: FU2; 6: FU3; 7: FU4; 8: FU5	
CT_neck	Imaging	0-1	—	0: neck lymph nodes not involved by tumor via CT scan	
				1: neck lymph nodes involved by tumor via CT scan	
CT_thorax	Imaging	0-1	—	0: thorax lymph nodes not involved by tumor via CT scan	
				1: thorax lymph nodes involved by tumor via CT scan	
CT_abdomen	Imaging	0-1	—	0: abdomen lymph nodes not involved by tumor via CT scan	
				1: abdomen lymph nodes involved by tumor via CT scan	
CT_pelvis	Imaging	0-1	—	0: pelvis lymph nodes not involved by tumor via CT scan	
				1: pelvis lymph nodes involved by tumor via CT scan	
NLTB	Imaging	0-1	—	Nodal low tumor burden. 1: if there is (1) a nodal involvement (SupraDia = 1 or SubDia = 1 and EN = 0), and (2) BMInf = 1, and (3) bulk = 1. Otherwise, the attribute assumes value 0	
ENLTB	Imaging	0-1	—	Extranodal low tumor burden: 1 = if there is (1) an EN involvement (SupraDia = 0 and SubDia = 0 and EN = 1), and (2) BMInf = 1, and (3) bulk = 1. Otherwise the attribute assumes value 0	
PET	Imaging	0-9	—	1: not pathologic; 2: pathologic; 3: not done	
ID	—	—	—	Primary key of the table: it is the internal ID of the table	LAB
codeSubject	Protocol	0-9,999	—	Unique ID of the accrued subjects. This ID code is defined by the clinical trial sponsor	
Marker	Molecular laboratory	0-9	—	Type of marker used for tumor burden assessment. 0: no marker detection; 1: IgH; 2: BCL1; 3: both	
NesPCR_BM_IgH_dia	Molecular laboratory	0-1	—	Qualitative assessment of IgH on bone marrow. 0: no marker detection; 1: yes marker	
NesPCR_PB_IgH_dia	Molecular laboratory	0-1	—	Qualitative assessment of IgH on peripheral blood. 0: no marker detection; 1: yes marker	
NesPCR_BM_BCL1_dia	Molecular laboratory	0-1	—	Qualitative assessment of BCL1 on bone marrow. 0: no marker detection; 1: yes marker	
NesPCR_PB_BCL1_dia	Molecular laboratory	0-1	—	Qualitative assessment of BCL1 on peripheral blood. 0: no marker detection; 1: yes marker	
qPCR_BM_IgH	Molecular laboratory	0.00000001-9	—	Quantitative PCR at diagnosis. 10 <sup>-8</sup> → no marker detection; 10 <sup>-6</sup> → BQR: > 10 <sup>-6</sup> → yes marker	
qPCR_PB_IgH	Molecular laboratory	0.00000001-9	—	Quantitative PCR at diagnosis. 10 <sup>-8</sup> → no marker detection; 10 <sup>-6</sup> → BQR: > 10 <sup>-6</sup> → yes marker	
qPCR_BM_BCL1	Molecular laboratory	0.00000001-9	—	Quantitative PCR at diagnosis. 10 <sup>-8</sup> → no marker detection; 10 <sup>-6</sup> → BQR: > 10 <sup>-6</sup> → yes marker	
qPCR_PB_BCL1	Molecular laboratory	0.00000001-9	—	Quantitative PCR at diagnosis. 10 <sup>-8</sup> → no marker detection; 10 <sup>-6</sup> → BQR: > 10 <sup>-6</sup> → yes marker	

(Continued on following page)



**TABLE 1.** Description of the Principal Variables Encoded in the DW (Continued)

Variable	Class of Data	Validity Range	Unit of Measure	Description	Source
sampledate_baseline	—	—	—	Date of analyses on the samples at baseline	LAB
ID	—	—	—	Primary key of the table: it is the internal ID of the table	
codeSubject	Protocol	—	—	Unique ID of the accrued subjects. This ID code is defined by the clinical trial sponsor	LAB
N_timepoint	Temporal	—	—	1: restaging1; 2: restaging2; 3: restaging3; 4: FU1; 5: FU2; 6: FU3; 7: FU4; 8: FU5	
NesPCR_BCL1_BM	Molecular laboratory	—	—	Qualitative MRD assessment. 0: neg; 1: pos	
NesPCR_IGH_BM	Molecular laboratory	—	—	Qualitative MRD assessment. 0: neg; 1: pos	
NesPCR_BCL1_PB	Molecular laboratory	—	—	Qualitative MRD assessment. 0: neg; 1: pos	
NesPCR_IGH_PB	Molecular laboratory	—	—	Qualitative MRD assessment. 0: neg; 1: pos	
qPCR_BM_BCL1	Molecular laboratory	—	—	Quantitative MRD assessment. $10^{-8} \rightarrow$ no marker detection; $10^{-6} \rightarrow$ BQR: $> 10^{-6} \rightarrow$ yes marker	
qPCR_BM_IGH	Molecular laboratory	—	—	Quantitative MRD assessment. $10^{-8} \rightarrow$ no marker detection; $10^{-6} \rightarrow$ BQR: $> 10^{-6} \rightarrow$ yes marker	
qPCR_PB_BCL1	Molecular laboratory	—	—	Quantitative MRD assessment. $10^{-8} \rightarrow$ no marker detection; $10^{-6} \rightarrow$ BQR: $> 10^{-6} \rightarrow$ yes marker	
qPCR_PB_IGH	Molecular laboratory	—	—	Quantitative MRD assessment. $10^{-8} \rightarrow$ no marker detection; $10^{-6} \rightarrow$ BQR: $> 10^{-6} \rightarrow$ yes marker	
sampledate_MRD_REST	Molecular laboratory	—	—	Date of analyses on the samples at either a restaging or a follow-up	
delta_sampledate	—	—	d	Difference of date between sampledate_MRD_REST and sampledate_baseline	
Id_dqa	—	—	—	Primary key of the table: it is the internal ID of the table	—
n_timepoint	Data quality	—	—	0: No_DQ; 1: PM-1; 2: PM-2; 3: PM-3; 4: PM-4	
dqa_date	Data quality	—	—	Timestamp related to the DQ check	
variables	Data quality	—	—	List of relevant variables involved in DQ analysis	
categories	Data quality	—	—	List of categories associated to each relevant variable involved in DQ analysis	
completeness	Data quality	—	—	Completeness DQ dimension assessment in %	
plausibility	Data quality	—	—	Plausibility DQ dimension assessment in %	
concordance	Data quality	—	—	Concordance DQ dimension assessment in %	
conformance	Data quality	—	—	Conformance DQ dimension assessment in %	
correctness	Data quality	—	—	Correctness of the calculated fields in the DQ dimension assessment in %	
dqa_note	Data quality	—	—	Note about DQ check	
idCenter	Data quality	—	—	Center ID associated to the DQ check	

NOTE. All the principal variables encoded in the DW, grouped by tables, were described in detail. For each variable the following information was represented: class of data (eg, protocol or laboratory variable), validity range, unit of measure, description, and source. The list provided contained only a subgroup of variables; in the complete version of the DW, 226 variables were encoded.

Abbreviations: AA, Ann Arbor; BMI, body mass index; BSA, body surface area; BQR, below the quantitative range; CT, computed tomography; DQ, data quality; DW, data warehouse; EN, extranodal; FU, follow-up; MCL, mantle cell lymphoma; MIPI, MCL International Prognostic Index; MIPI-c, MCL International Prognostic Index c; MRD, minimal residual disease; neg, negative; NLTB, nodal low tumor burden; OS, overall survival; PCR, polymerase chain reaction; PET, positron emission tomography; PFS, progression-free survival; pos, positive; RND, randomization.

TABLE 2. Results of the Data Quality Assessment After Each Milestone

Data Groups and Relative Timepoints			Relevance		Completeness		Plausibility		Concordance	
Expected Data			Fts Name		Cases		Cases		Cases	
			No.							
No DQ	2,400		codeSubject, Center_ID, Age, Sex, W, H, BMI, BSA		8		2,400 100.0		2,400 100.0	
PM-1							2,400 100.0		2,400 100.0	
PM-2							2,400 100.0		2,400 100.0	
PM-3							2,400 100.0		2,400 100.0	
PM-4							2,400 100.0		2,400 100.0	
Protocol_data			1,500							
No DQ			PFS, Progression, OS, Arm, RND		5		1,500 100.0		1,500 100.0	
PM-1							1,500 100.0		1,500 100.0	
PM-2							1,500 100.0		1,500 100.0	
PM-3							1,500 100.0		1,500 100.0	
PM-4							1,500 100.0		1,500 100.0	
Clinical_data			1,500							
No DQ			AAstage, MIPI, ECOGps, Bulky, Sym		5		1,473 98.2		1,481 98.7	
PM-1							1,490 99.3		1,482 98.8	
PM-2							1,494 99.6		1,486 99.1	
PM-3							1,499 99.9		1,489 99.3	
PM-4							1,500 100.0		1,498 99.9	
Laboratory_data			2,700							
No DQ			LDH, LDHMax, WBC, ANC, L, Hb, PLTs, B2, B2Max		9		2,583 95.7		2,455 90.9	
PM-1							2,664 98.7		2,451 90.8	
PM-2							2,670 98.9		2,495 92.4	
PM-3							2,672 99.0		2,499 92.6	
PM-4							2,691 99.7		2,543 94.2	
Pathology_data			2,100							
No DQ			Ki67, BMInf, BMInfperc, Hist, IgHomo, flowBM, flowPB		7		1,578 75.1		2,067 98.4	
PM-1							1,807 86.0		2,067 98.4	
PM-2							1,880 89.5		2,093 99.7	
PM-3							1,880 89.5		2,093 99.7	
PM-4							1,893 90.1		2,089 99.5	

(Continued on following page)

**TABLE 2.** Results of the Data Quality Assessment After Each Milestone (Continued)

Data Groups and Relative Timepoints			Relevance		Completeness		Plausibility		Concordance	
			Expected Data	Fts Name	No.	Cases	%	Cases	%	Cases
MRD_data			1,200							
No DQ				Nested_BMIGH, Nested_PBIGH, qPCR_BMIGH, qPCR_PBIGH	4	808	67.3	1,200	100.0	1,199
PM-1						873	72.8	1,200	100.0	1,200
PM-2						986	82.2	1,200	100.0	1,200
PM-3						986	82.2	1,200	100.0	1,200
PM-4						986	82.2	1,200	100.0	1,200
Imagingdata			1,200							
No DQ				SUP_dia, SUPRA_dia, EN, PET	4	1,135	94.6	1,200	100.0	1,200
PM-1						1,191	99.3	1,200	100.0	1,200
PM-2						1,191	99.3	1,200	100.0	1,200
PM-3						1,191	99.3	1,200	100.0	1,200
PM-4						1,194	99.5	1,200	100.0	1,200
Total			12,600							
No DQ				—	42	11,477	91.09	12,303	97.6	12,561
PM-1						11,925	94.64	12,300	97.6	12,567
PM-2						12,121	96.20	12,374	98.2	12,563
PM-3						12,128	96.25	12,381	98.3	12,565
PM-4						12,164	96.54	12,430	98.7	12,582

NOTE. For each group of relevant variables, the values of completeness, plausibility, and concordance were represented after each of the five milestones.

Abbreviations: ANC, absolute neutrophils count; B2,  $\beta$ 2 microglobulins; B2Max, maximum level of B2 for laboratory; BMI, body mass index; BSA, body surface area; DQ, data quality; EN, extranodal; fts, features; H, height; Hb, hemoglobin level; IgH\_omo, IgH germline omology; L, lymphocytes level; OS, overall survival; PET, positron emission tomography; PLTs, platelets level; PFS, progression-free survival; PM, postmilestones.

and restaging. In these situations, the N\_timepoint attribute was only added to the restaging table (clinical\_data\_restaging and mrd\_restaging tables).

The DQ table (brown in Fig 1) was integrated to the ETL process in linkage to the center table. It collected each DQ dimension assessed in time (dqa\_date attribute) according to each relevant variable.

### Relevant Patient Features


The collected features (fts) are shown in Table 1 (fully detailed in Data Supplement). To increase signal-to-noise rate for the FIL-MCLO208 context,<sup>25</sup> 42 baseline fts have been considered relevant by clinicians for a total of 12,600 expected data: 1) 8 fts from the Demography\_& Morphometric\_data group retrieved from eCRFs: code-Subjects, Center\_ID, age, sex, weight (W), height (H), body mass index (BMI), and body surface area (BSA); 2) 5 fts from the Protocol\_data group retrieved from eCRFs: progression, PFS, overall survival (OS), randomization inclusion (RND), and consequent arm of treatment (ARM); 3) 5 fts from the Clinical\_data group retrieved from eCRFs: AA stage, B symptoms<sup>27</sup> (sym), bulky disease, Eastern Co-operative Oncology Group performance status (ECOGps), and MIPI; 4) 9 fts from the Laboratory\_data group retrieved from eCRFs: LDH and relative maximum (LDHMax), WBC, absolute neutrophils count (ANC), lymphocytes (L),

hemoglobin (Hb), platelets (PLTs),  $\beta_2$ -microglobulins (B2M) and relative maximum (B2Max); 5) 7 fts from the Pathology\_data group: either blastoid or normal histology (Hist), percentage of tumor infiltration level detected by flow cytometry, both in bone marrow and peripheral blood (FlowBM and FlowPB), Ki67, BMinf and relative quantitative value in percentage (BMinfperc), and IgH germline omology (IgH\_Omo); 6) 4 fts from the MRD\_data group: IgH marker detected by both nested and real-time quantitative polymerase chain reaction (PCR) in bone marrow and peripheral blood (Nested\_BMIgH, Nested\_PBIgH, qPCRBMlgH, qPCRPBIgH); 7) 4 fts from the Imaging\_data group retrieved from eCRFs: sub- and supra-diaphragmatic nodal (SUB\_dia and SUPRA\_dia) and extranodal (EN) site tumor involvement assessed by both computed tomography and positron emission tomography.

### DQ Monitoring

The benefits of performing DQ checks were assessed by the quality of the knowledge that might be extracted from data. The assessment allowed monitoring of the DQ dimensions for each clinical site active in the trial.

As listed in Table 2, overall 189,000 checks were provided in time according to the DQ dimensions. Among these, overall C increased from 91.09% (n = 11,477) to 96.54% (n = 12,164) from No\_DQ to PM-4. Moreover, both




**FIG 2.** Results of the data quality (DQ) assessment applied after each milestone. (A-C) Radial graphs of (A) the completeness, (B) the plausibility, and (C) the concordance indexes computed after each milestone for each center. (D) The same indexes represented by bar diagrams divided into small centers (< 5 patients enrolled), medium centers (5-9 patients enrolled), and large centers ( $\geq 10$  patients enrolled). PM, post milestones.

overall P and CON increased 1.1% (n = 127) and 0.2% (n = 21) from No\_DQ to PM-4, respectively. According to each group of data, for both Pathology\_data and MRD\_data categories, C increased in time from 75.1% (n = 1,578) to 82.2% (n = 1,893) and from 67.3% (n = 808) to 82.2% (n = 986), respectively. Moreover, the P dimension improved up to 94.2% (n = 2,543) for Laboratory\_data group at PM-4, whereas the CON dimension slightly increased in 1.1% (n = 24) for Clinical\_data group from No\_DQ to PM-4.

Figure 2 shows the values assumed across the sites: the radial graphs described C (Fig 2A), P (Fig 2B), and CON (Fig 2C) dimensions for the relevant fts retrieved from

eCRFs after each milestone. For instance, C increased from 59.4% (n = 104) to 96.6% (n = 169) from No\_DQ to PM-4 for center 52. Furthermore, the P dimension increased for center 49 from 82.8% (n = 24) to 93.1% (n = 27). The three-dimensional bar chart depicted the averaged DQ dimensions across the sites classified in small, medium, and large enrollers. A statistically significant increase from No-DQ to PM-4 was recorded for both medium (C: from 85.4% to 97.1%,  $P = .001$ ; P: from 96.9% to 97.8%,  $P = .047$ ; COR: from 96.9% to 97.8%,  $P = .002$ ) and large centers (C: from 93.8% to 97.3%,  $P = .002$ ; P: from 95.2% to 97.8%,  $P = .011$ ; COR: from 99.8% to 99.9%,  $P = .0321$ ), respectively.



**FIG 3.** Outcome analysis after the data quality (DQ) application for data retrieved from the FIL-MCL0208 clinical study. Progression-free survival (PFS) curves calculated (A) at the beginning of the study (No\_DQ timepoint, n = 277), and (B) after the last milestone (PM-4 time point, n = 300) for the three classes of Mantle Cell Lymphoma International Prognostic Index (MIPI). The log-rank test results are reported in terms of the  $P$  values obtained comparing the curves of adjacent classes: low (L-MIPI) versus intermediate classes (I-MIPI;  $P < .001$ ), I-MIPI versus high classes (H-MIPI;  $P = .626$ ) for A; L-MIPI versus I-MIPI ( $P < .001$ ), I-MIPI versus H-MIPI ( $P = .113$ ) for B. PFS discrimination was based on the infiltration of disease detected by flow cytometry from (C) the No\_DQ time point (n = 120) to (D) the PM-4 time point (n = 252). The log-rank test results are reported in terms of  $P$  values obtained comparing the curves of adjacent classes: < median versus ≥ median ( $P < .567$ ) for C (median = 4.45%); < median versus ≥ median ( $P < .012$ ) for D (median = 6.55%). Significance level set at .05.

## Impact of DQ on Clinical Outcome

Figure 3 shows the PFS plots drawn at the No\_DQ time point and after PM-4, stratified for both MIPI risk classes (Fig 3A) and flowBM (Fig 3B). The results demonstrate that applying the four steps of DQ management improved the patients' outcome discrimination. This is sustained by the improvement in the *P* values, which, after the DQ management procedure (Table 2), are lower than their initial values. In particular, in the MIPI classification, the number of patients attributed to each risk class varies after the application of the DQ management, together with an improvement in the total number of patients studied. The MIPI risk category was reclassified for 23 patients not classified at No\_DQ, as follows: 12 were classified as low risk, eight as intermediate risk, and three as high risk. Moreover, 10 IR patients were reclassified as low risk, and 9 high-risk patients were downgraded. Furthermore, focusing on tumor infiltration by flow cytometry at diagnosis, the DQ analysis identified 133 MVs at No\_DQ. These MVs were recovered at PM-4. In this case, the *P* value became significant (from .567 to .012) when assuming the median of the observations as the cutoff (Fig 3B).

## DISCUSSION

In this study, a large collection of clinical and biologic data from the FIL-MCL0208 open-label, randomized, phase III clinical trial underwent engineering using DW technology. Starting from the analysis of the variables retrieved from the eCRFs, a model of the DW ensured a rational and easily accessible frame for the collection of translational data. This article presents the results related to baseline variables with the objectives of developing a DQ control strategy and improving outcome analysis according to the clinical trial primary end points.

The interest in using DW techniques in clinical research is growing.<sup>5,8,30-32</sup> The DW (Fig 1) allowed every single patient to be associated with several records belonging to other categories. This aspect was important to monitor data redundancy. The data collection using a structured DW, rather than a classic two-dimensional database, facilitated the implementation of a set of controls for monitoring the centers' accuracy and the quality of data. As we detailed previously, the MIPI risk classification accuracy at baseline can assess the knowledge obtained with several techniques of data processing.<sup>33</sup> Here, we observed completeness, plausibility, and concordance dimensions<sup>24,25</sup> to better understand any cause of DQ inconsistency. In particular, according to completeness dimension, although an overall decrease of missing data has been recorded, not all of the issues queried to the sites have been recovered. This was probably related to the weak accuracy by centers in compiling eCRFs. Missing data are common in open-labeled, multicenter clinical trials, and to systematically map causes could be tricky. Thus, because of the integration of both clinical and molecular data frames, the determination of the concordance dimension has been automatically handled by investigator-driven rules (Table 3). Moreover, both granularity and structuredness dimensions were preserved for tables connected to subtables (eg, study\_interruption table). According to conformance and correctness, the ETL prevented the occurrence of additional incongruencies.

The proposed procedure was observed by assessing the PFS. Our results showed that, after four steps of DQ management, there was better separation of the PFS curves related to the risk of relapse of patients with MCL, classified according to both MIPI (three groups) and the tumor infiltration detected by flow cytometry (two groups). The proposed procedure allowed us to query the MIPI classification (Fig 3A) for 61 patients. This was principally the result of a not-plausible data entry (ie, WBC values at  $10^6/L$  instead of  $10^9/L$ ). Moreover, the PFS curves assessed using the patients' tumor infiltration data (Fig 3B) show a dramatic decrease of MVs (from 180 to 48), and this led to an improvement in stratification by the median of observations.

Although there are recommended CDMs,<sup>34</sup> the decision to create a new relational model has been made according to the clinical trial sponsor: the scientific debate on standardization of the MRD assessment in onco-hematology requires that sponsors handle a CDM strictly suited on this domain, which includes several unmapped data. Hence, the use of a standard CDM can be a limitation.<sup>35</sup> The weaknesses of applying DW concepts include the need for data integration using user-friendly eCRF platforms, which are believed to easily apply DQ strategies.<sup>36</sup> However, the benefits of the DW might overcome any effort to migrate to novel eCRF platforms during the data collection. Moreover, because of a lack of funds, investigator-sponsored trials

**TABLE 3.** Detailed Description of the Rules Used to Detect the Class of Incompatible Values (IN) for the Data Quality Management Procedure

No.	Rule
1	BMInf > 0 AND AASstage < IV
2	EN > 0 AND AASstage < IV
3	AASstage < IV AND BMInf > 0 AND EN > 0
4	AASstage < IV AND BMInf > 0 AND (flowBM > 15% OR flowPB > 15%)
5	AASstage < IV AND BMInf > 0 AND (qPCR_BM > $10^{-5}$ OR qPCR_PB > $10^{-5}$ )
6	AASstage < IV AND BMInf > 0 AND (flowBM > 15% OR flowPB > 15%) AND (qPCR_BM > $10^{-5}$ OR qPCR_PB > $10^{-5}$ )

NOTE. Rule 1: a subject with a disease infiltration detected on a bone marrow sample (BMInf) was incompatible with an Ann Arbor (AA) stage less than IV.<sup>27</sup> Rule 2: a subject with a disease detected via computed tomography scan on extranodal lymph node (EN) was incompatible with an AA stage less than IV.<sup>27</sup> Rule 3: rule 1 + rule 2. Rule 4: rule 1 + disease infiltration on either BM or peripheral blood (PB) at baseline > 15% detected by flow cytometry (flow).<sup>37</sup> Rule 5: rule 1 + disease infiltration on either BM or PB at baseline >  $10^{-5}$  detected via quantitative polymerase chain reaction technique (qPCR).<sup>37</sup> Rule 6: rule 4 + rule 5.



might suffer as a result of suboptimal data-monitoring strategies. The post hoc application of a newly designed relational DW tool amended the negative impact of these issues, allowing a novel organization of clinical

trial data more oriented to outcome analysis. In conclusion, the developed DW is the foundation of clinical decision support systems based on data-mining techniques.

## AFFILIATIONS

<sup>1</sup>Università di Torino, Turin, Italy

<sup>2</sup>Politecnico di Torino, Turin, Italy

<sup>3</sup>Unit of Clinical Epidemiology, Centro di Prevenzione Oncologica (CPO), Città della Salute e della Scienza di Torino, Hospital of Turin, Turin, Italy

<sup>4</sup>University of Padua, Padua, Italy

<sup>5</sup>Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Policlinico San Matteo, University of Pavia, Pavia, Italy

<sup>6</sup>Infermi Hospital, Rimini, Italy

<sup>7</sup>University of Genoa, Ospedale Policlinico San Martino, IRCCS per l'Oncologia, Genoa, Italy

<sup>8</sup>IRCCS San Raffaele Scientific Institute, Milan, Italy

<sup>9</sup>Oncology Unit Clinica Humanitas/Gavazzeni, Bergamo, Italy

<sup>10</sup>Division of Hematology, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

## CORRESPONDING AUTHOR

Gian Maria Zaccaria, PhD, Hematology Unit, Department of Molecular Biotechnology and Health Science, University of Turin, Via Genova 3, 10126 Turin, Italy; e-mail: gianmaria.zaccaria@unito.it.

## PRIOR PRESENTATION

Presented at the American Society of Hematology meeting, Atlanta, GA, December 9-12, 2017.

## SUPPORT

Supported by Progetto di Ricerca Sanitaria Finalizzata 2009 Grant No. RF-2009-1469205 and 2010 Grant No. RF-2010-2307262 (S.C.), A.O. S. Maurizio, Bolzano/Bozen, Italy; Fondi di Ricerca Locale, Università degli Studi di Torino, Italy; Fondazione Neoplasie Del Sangue, Torino, Italy; Fondazione CRT projects No. 2016.0677 and 2018.1284, Torino, Italy; and Fondazione DaRosa, Torino, Italy.

## AUTHOR CONTRIBUTIONS

**Conception and design:** Gian Maria Zaccaria, Simone Ferrero, Samanta Rosati, Marco Ghislieri, Gabriella Balestra, Mario Boccadoro, Marco Ladetto

**Provision of study material or patients:** Gian Maria Zaccaria, Simone Ferrero, Andrea Evangelista, Luca Arcaini, Anna Lia Molinari, Filippo Ballerini, Andres Ferreri, Sergio Cortelazzo, Marco Ladetto

**Collection and assembly of data:** Gian Maria Zaccaria, Simone Ferrero, Marco Ghislieri, Elisa Genuardi, Andrea Evangelista, Rebecca Sandrone, Daniela Barbero, Luca Arcaini, Anna Lia Molinari, Filippo Ballerini, Andres Ferreri, Paola Omedè, Alberto Zamò, Sergio Cortelazzo, Marco Ladetto

**Data analysis and interpretation:** Gian Maria Zaccaria, Simone Ferrero, Samanta Rosati, Marco Ghislieri, Elisa Genuardi, Andrea Evangelista, Cristina Castagneri, Mariella Lo Schirico, Gabriella Balestra, Mario Boccadoro, Sergio Cortelazzo, Marco Ladetto

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/cci/author-center](http://ascopubs.org/cci/author-center).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://OpenPayments)).

### Simone Ferrero

**Consulting or Advisory Role:** Janssen-Cilag, EUSA Pharma

**Speakers' Bureau:** Janssen-Cilag, Gilead Sciences, SERVIER

**Research Funding:** Gilead Sciences

**Travel, Accommodations, Expenses:** Roche, SERVIER, Sanofi, Janssen-Cilag, EUSA Pharma, Gentili

### Luca Arcaini

**Consulting or Advisory Role:** Roche, Celgene, Janssen-Cilag, Verastem Oncology

**Speakers' Bureau:** Celgene

**Research Funding:** Gilead

**Travel, Accommodations, Expenses:** Roche, Celgene, Gilead Sciences

### Andres Ferreri

**Consulting or Advisory Role:** Kite-Gilead, Celgene, SERVIER

**Research Funding:** Celgene (Inst), Roche (Inst)

**Travel, Accommodations, Expenses:** Gilead Sciences, MolMed, Takeda, Roche

### Paola Omedè

**Consulting or Advisory Role:** Janssen

### Mario Boccadoro

**Honoraria:** Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, AbbVie

**Research Funding:** Sanofi (Inst), Celgene (Inst), Amgen (Inst), Janssen (Inst), Novartis (Inst), Bristol-Myers Squibb (Inst), Mundipharma (Inst)

### Marco Ladetto

**Honoraria:** AbbVie, Acerta Pharma, Amgen, Archigen Biotech, ADC Therapeutics, Celgene, Gilead Sciences, Johnson & Johnson, Jazz Pharmaceuticals, Pfizer, Roche, Sandoz, Takeda

No other potential conflicts of interest were reported.

## REFERENCES

1. Kessel KA, Combs SE: Review of developments in electronic, clinical data collection, and documentation systems over the last decade - are we ready for big data in routine health care? *Front Oncol* 6:75, 2016
2. Inmon WH: Building the data warehouse. New York, NY, Wiley Computer Pub, 1996



3. Aziz HA: Handling big data in modern healthcare. *Lab Med* 47:e38-e41, 2016
4. Karami M, Rahimi A, Shahmirzadi AH: Clinical data warehouse: An effective tool to create intelligence in disease management. *Health Care Manag (Frederick)* 36:380-384, 2017
5. Sylvestre E, Bouzillé G, Chazard E, et al: Combining information from a clinical data warehouse and a pharmaceutical database to generate a framework to detect comorbidities in electronic health records. *BMC Med Inform Decis Mak* 18:9, 2018
6. Shortliffe EH, Cimino JJ: *Biomedical informatics: Computer applications in health care and biomedicine* (ed 4). London, United Kingdom, Springer, 2014
7. Han J, Kamber M, Pei J: *Data Mining: Concepts and Techniques*. 2012 <http://myweb.sabanciuniv.edu/rdehkharghani/files/2016/02/The-Morgan-Kaufmann-Series-in-Data-Management-Systems-Jiawei-Han-Micheline-Kamber-Jian-Pei-Data-Mining-Concepts-and-Techniques-3rd-Edition-Morgan-Kaufmann-2011.pdf%0Ahttp://scholar.google.com/schol>
8. Hripcsak G, Duke JD, Shah NH, et al: *Observational Health Data Sciences and Informatics (OHDSI): Opportunities for observational researchers*. *Stud Health Technol Inform* 216:574-578, 2015
9. Huser V, Kahn MG, Brown JS, et al: Methods for examining data quality in healthcare integrated data repositories. <https://psb.stanford.edu/psb-online/proceedings/psb18/wrkshop-methods.pdf>
10. Zaccaria GM, Ferrero S, Evangelista A, et al: Delphi, a data warehouse to discover associations between variables in clinical trials: Application to the Fondazione Italiana Linfomi (FIL) MCL0208 phase III trial. *Blood* 130, 2017 (suppl 1; abstr 3451)
11. Wah TY, Sim OS: Evaluating a data warehouse for lymphoma diagnosis and treatment decision support system, in *Proceedings - UKSim 4th European Modelling Symposium on Computer Modelling and Simulation, EMS2010*. 2010, pp 57-62
12. Wysham NG, Wolf SP, Samsa G, et al: Integration of electronic patient-reported outcomes into routine cancer care: An analysis of factors affecting data completeness. *JCO Clin Cancer Inform* 10.1200/CCI.16.00043
13. Society for Clinical Data Management: *Good Clinical Data Management Practices*. 2013. <https://www.mci-registrations.com/be-bruga/mci-registrations/scdm/files/gcdmp/en/2013/Full%20GCDMP%20Oct%202013.pdf>
14. Lee K, Weiskopf N, Pathak J: A framework for data quality assessment in clinical research datasets. *AMIA Annu Symp Proc* 2017:1080-1089, 2018
15. Callahan TJ, Bauck AE, Bertoch D, et al: A comparison of data quality assessment checks in six data sharing networks. *EGEMS (Wash DC)* 5:8, 2017
16. Kahn MG, Callahan TJ, Barnard J, et al: A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data: a harmonized data quality assessment terminology and framework for. *EGEMS (Wash DC)* 4:1244, 2016
17. Niimi M, Yamamoto S, Fukuda H, et al: The influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A). *Jpn J Clin Oncol* 32:19-26, 2002
18. Sariyar M, Borg A, Heidinger O, et al: A practical framework for data management processes and their evaluation in population-based medical registries. *Inform Health Soc Care* 38:104-119, 2013
19. Dietrich G, Krebs J, Fette G, et al: Ad hoc information extraction for clinical data warehouses. *Methods Inf Med* 57:e22-e29, 2018
20. Weiskopf NG, Weng C: Methods and dimensions of electronic health record data quality assessment: Enabling reuse for clinical research. *J Am Med Inform Assoc* 20:144-151, 2013
21. Lu Z, Su J: Clinical data management: Current status, challenges, and future directions from industry perspectives. *Open Access J Clin Trials* 2:93, 2010
22. Hoster E, Dreyling M, Klapper W, et al: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. *Blood* 111:558-565, 2008
23. Ladetto M, Ferrero S, Evangelista A, et al: Lenalidomide maintenance after autologous transplantation prolongs PFS in young MCL patients: Results of the randomized phase III MCL 0208 trial from Fondazione Italiana Linfomi (FIL). *Blood* 132:401, 2018
24. Naham M: Data quality in clinical research, in Richesson RL, Andrews JE (eds): *Clinical Research Informatics*. Springer Science & Business Media, 2012. <http://people.dbmi.columbia.edu/~chw7007/papers/chapter%2010.pdf>
25. Weiskopf N, Bakken S, Hripcsak G, et al: A data quality assessment guideline for electronic health record data reuse. *EGEMS (Wash DC)* 5:14, 2017
26. Katzenberger T, Petzoldt C, Höller S, et al: The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. *Blood* 107:3407, 2006
27. Dreyling M, Ferrero S, Hermine O: How to manage mantle cell lymphoma. *Leukemia* 28:2117-2130, 2014
28. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. *J Clin Oncol* 25:579-586, 2007
29. Levene M, Loizou G: Why is the snowflake schema a good data warehouse design? *Inf Syst* 28:225-240, 2003
30. Yamamoto K, Ota K, Akiya I, et al: A pragmatic method for transforming clinical research data from the research electronic data capture "REDCap" to Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM): Development and evaluation of REDCap2SDTM. *J Biomed Inform* 70:65-76, 2017
31. Wisniewski MF, Kieszkowski P, Zagorski BM, et al: Development of a clinical data warehouse for hospital infection control. *J Am Med Inform Assoc* 10:454-462, 2003
32. Lowe HJ, Ferris TA, Hernandez PM, et al: STRIDE—An integrated standards-based translational research informatics platform. *AMIA Annu Symp Proc* 2009: 391-395, 2009
33. Zaccaria GM, Rosati S, Castagneri C, et al: Data quality improvement of a multicenter clinical trial dataset. 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Jeju, Korea, July 11-15, 2017
34. Weeks J, Pardee R: Learning to share health care data : A brief timeline of influential common data models and distributed health data networks in U.S. health care research. *EGEMS (Wash DC)* 7:4, 2019
35. Garza M, Del Fiol G, Tenenbaum J, et al: Evaluating common data models for use with a longitudinal community registry. *J Biomed Inform* 64:333-341, 2016
36. Harris PA, Taylor R, Thielke R, et al: Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 42:377-381, 2009
37. Cheminant M, Derriex C, Touzart A, et al: Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: An EU-MCL and LYSA study. *Haematologica* 101:336-345, 2016
38. Ghielmini M, Vitolo U, Kimby E, et al: ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). *Ann Oncol* 24:561-576, 2013
39. Mallick R, Kumar Lal B, Daugherty C: Relationship between patient-reported symptoms, limitations in daily activities, and psychological impact in varicose veins. *J Vasc Surg* 2:224-237, 2017

